Latest News

The payout has grown every year since 2012 -- but the quarterly payments are uneven, and the growth has slowed.

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company’s shift toward an end-to-end, AI-enabled drug discovery and development platform. Kha

The market has a history of reacting the wrong way to economic data, but that doesn't mean you can ignore it.

Hyperliquid may be soaring, but how much longer can it hold on to its market-leading position?

With resilient businesses, solid financial performance, and visible growth opportunities, these five TSX stocks offer compelling opportunities for long-term investors.

Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company’s mental health treatment pipeline. Speaki

Loblaw is a core holding candidate for a long-term TFSA. Canadians can consider dollar-cost averaging into a position over time to reduce market-timing risk.

The investment bank's stock is in a prime position to head higher.

Canada’s dividend pioneer is the ultimate anchor stock and forever holding in a TFSA.

Nvidia is guiding for 70% top-line growth in its next fiscal year, but the chipmaker has regularly proven too conservative with its guidance in the past.

The software maker is growing faster than ever, yet its shares sit about where they were a year ago. So is the stock finally reasonably priced?

The unlocking of SpaceX shares is reshaping the communications sector.

Aurora Innovation (NASDAQ:AUR) is preparing to expand its autonomous-trucking operations through a second-generation hardware rollout, a planned transition toward a driver-as-a-service model and additional manufacturing relationships, Co-founder and CEO Chris Urmson said at the Morgan Stanley Laguna

The sale of 5,578 shares appears to be a routine transaction.

Yields are rising, and investors are selling REITs, opening up an opportunity to buy reliable, high-yield dividend stocks for long-term investors.

It's one of four key sector holdings in the company's portfolio.

This expensive quantum computing stock isn't growing as fast as it seems.

Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference. Chumi Khurana, senior vice president of U.S. Oncology

The index has climbed in 34 of the last 41 fourth quarters. The seven misses are the part worth studying.

Coca-Cola isn't cheap, but it is executing well in a difficult market and has an incredible dividend history.

Investors are growing increasingly concerned about AI-powered threats.

Pfizer's rebound is well underway.

SpaceX stock has rebounded nicely since its prior sell-off, but can the momentum last until its next earnings report?

Meta has fallen behind the other frontier labs recently, but that may have changed with the introduction of the Muse app.

WW International (NASDAQ:WW) executives outlined the company’s efforts to reposition its weight-management business around behavioral support, telehealth and GLP-1 medications, following a restructuring that substantially reduced its debt burden. Speaking at Morgan Stanley’s healthcare conference,